NCT05389267View on ClinicalTrials.gov

Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients.

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

July 5, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions

GlaucomaOcular Hypertension

Interventions

DRUG

Kinezodianone R hydrochloride

Eyedrops

DRUG

Placebo

Placebo

Trial Locations (1)

91204

Dr EL-HARAZI, Glendale

Sponsors

Lead Sponsor

Laboratoires Thea

All Listed Sponsors

lead

Laboratoires Thea

INDUSTRY